share_log

HC Wainwright & Co. Maintains Buy on Bellerophon Therapeutics, Lowers Price Target to $2

HC Wainwright & Co. Maintains Buy on Bellerophon Therapeutics, Lowers Price Target to $2

HC Wainwright & Co.維持對Bellerophon Therapeutics的買入,將目標價下調至2美元
Benzinga ·  2023/06/06 06:35

HC Wainwright & Co. analyst Andrew Fein maintains Bellerophon Therapeutics (NASDAQ:BLPH) with a Buy and lowers the price target from $30 to $2.

HC Wainwright & Co. 分析師安德魯·費恩維持Bellerophon Therapeutics(納斯達克股票代碼:BLPH)的買入,並將目標股價從30美元下調至2美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論